Back

TTY Biopharm maps three growth engines after record NT$3.17 billion first-half revenue

Verifying
  • TTY Biopharm outlined Aumolertinib, Lipo-AB and new antibiotics as next year's growth engines.
  • NT$3.17 billion first-half revenue and NT$3.42 earnings per share reached historical records.
  • Lipo-AB approvals cover Australia, Saudi Arabia and Jordan, with sales activities underway.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.